2. Search Result
Search Result
Results for "

dose-response

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153552
    NH2-UAMC1110

    		FAP Cancer
    NH2-UAMC1110 is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose-response, and has been used for tumor diagnosis. NH2-UAMC1110 introduces an active amino group into its structure, enabling it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.), thereby synthesizing molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling processes. Its key activity is high targeting and high affinity, and its core function is to be coupled with bifunctional chelators (such as DOTA, DATA5m) as a targeting module. NH2-UAMC1110 can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .
    NH2-UAMC1110
  • HY-15301
    CC0651

    		E1/E2/E3 Enzyme Cancer
    CC0651 is an allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. CC0651 potently (IC50=1.72 μM) inhibits the ubiquitination of p27 Kip1, as confirmed by dose-response analysis.
    CC0651
  • HY-75577
    4-Amino-3-methoxybenzoic acid

    		Drug Intermediate Cancer
    4-Amino-3-methoxybenzoic acid is a drug intermediate that can be used to construct benzothiazole compounds with anti-breast cancer activity .
    4-Amino-3-methoxybenzoic acid
  • HY-P3220
    [D-Asn5]-Oxytocin

    		Oxytocin Receptor Endocrinology
    [D-Asn5]-Oxytocin possesses very low specific oxytocic and vasodepressor activities. By cumulative dose-response studies for oxytocic activity, [D-Asn5]-Oxytocin has similar intrinsic activity to oxytocin .
    [D-Asn5]-Oxytocin
  • HY-125316
    AMG-151

    ARRY-403

    		 Endogenous Metabolite Metabolic Disease
    AMG-151 (ARRY-403) is a glucokinase agonist with fasting plasma glucose (FPG) lowering activity. AMG-151 showed a significant linear dose-response trend compared with placebo in a randomized, placebo-controlled Phase IIa study. The use of AMG-151 was associated with a higher incidence of hypoglycemia and hypertriglyceridemia. AMG-151 may serve as a potential compound for the inhibition of type 1 diabetes .
    AMG-151
  • HY-167689
    Parethoxycaine hydrochloride

    		Adrenergic Receptor Neurological Disease
    Parethoxycaine hydrochloride is an anesthetic with nerve conduction blocking activity. Parethoxycaine hydrochloride exhibits non-selective inhibitory effects on responses to various stimulants in rat vas deferens and guinea pig ileum muscles. Parethoxycaine hydrochloride has an enhanced effect on the action of norepinephrine, and its methyl bromide derivative also exhibits the same properties on the action of norepinephrine and potassium ions. Derivatives of parethoxycaine hydrochloride have significant effects on calcium dose-response curves, displaying different tissue and stimulant selectivities. The mechanism of action of Parethoxycaine hydrochloride involves the regulation of calcium transport processes .
    Parethoxycaine hydrochloride
  • HY-136831
    SR2640

    QMPB

    		 Leukotriene Receptor Inflammation/Immunology
    SR2640 is a highly efficient and selective LTD4/LTE4 antagonist that can specifically inhibit the smooth muscle contractions induced by LTD4 in the guinea pig ileum and trachea in a concentration-dependent manner, without affecting the contractions caused by histamine. SR2640 can concentration-dependently prevent the binding of 0.4 nM [3H] LTD4 to membrane receptors in guinea pig lung tissue, with an IC50 of 23 nM. SR2640 can shift the dose-response curve for bronchoconstriction induced by intravenous LTD4 in guinea pigs to the right, and the extent of this shift is positively correlated with the dose of SR2640 administered. SR2640 can be used in asthma research .
    SR2640
  • HY-118534
    Cyclobutyrol

    BRN-2209058

    		 Endogenous Metabolite Endocrinology
    Cyclobutyrol is a potent choleretic agent. Cyclobutyrol also inhibits biliary lipid secretion. Cyclobutyrol induces choleretic is unrelated to bile acids. Cyclobutyrol and bile acids do not compete for the hepatobiliar transport mechanisms[1]
    Cyclobutyrol
  • HY-111181
    A 56234

    		Sodium Channel Potassium Channel Metabolic Disease
    A 56234 is an orally active benzisoxazole diuretic. A 56234 produces dose-dependent diuresis, sodium and chloride excretion, significantly increases potassium excretion, and also slightly increases calcium, magnesium, and total protein excretion. A 56234 has shown uricosuric effects in animal studies
    A 56234
  • HY-182636
    MT16-001

    		Deubiquitinase Aldehyde Dehydrogenase (ALDH) Metabolic Disease Inflammation/Immunology Cancer
    MT16-001 is a cell-permeable UCHL1 inhibitor with an IC50 value of 580 nM. MT16-001 also exhibits considerable inhibitory activity against USP30, and shows selectivity for other UCH family deubiquitinases (DUBs) as well as the broader proteome. MT16-001 binds covalently to the cysteine residue at the active site of UCHL1, and forms covalent interactions with ALDH2, ALDH9A1 and GATD3A in intact cells. Meanwhile, as a cytotoxic agent, it displays a steep dose-response curve in human embryonic kidney cells. MT16-001 can be used for research on various cancers, liver fibrosis and pulmonary fibrosis .
    MT16-001
  • HY-118534A
    Cyclobutyrol sodium

    BRN-2209058 sodium

    		 Endogenous Metabolite Endocrinology
    Cyclobutyrol sodium is a potent choleretic agent. Cyclobutyrol sodium also inhibits biliary lipid secretion. Cyclobutyrol sodium induces choleretic is unrelated to bile acids. Cyclobutyrol sodium and bile acids do not compete for the hepatobiliar transport mechanisms[1]
    Cyclobutyrol sodium
  • HY-W816575
    MDI-403

    		RAR/RXR SARS-CoV Infection
    MDI-403 is a retinoic acid receptor (RAR) agonist with an EC50 value of less than 1 μM. MDI-403 exhibits significant antiviral activity against SARS-CoV-2, and can dose-dependently inhibit the expression of viral nucleoprotein (NP) and reduce the proportion of infected cells. MDI-403 mainly acts during the virus invasion stage. MDI-403 can be used in research on anti-SARS-CoV-2 .
    MDI-403

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: